HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Summary Full Text Full Text (PDF) All Versions of this Article: fj.05-4617fjev1 20/8/1203    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sotiropoulos, K. B. Articles by King, G. L. Search for Related Content PubMed PubMed Citation Articles by Sotiropoulos, K. B. Articles by King, G. L.

Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPAR agonist’s effects on edema and weight gain

Research Division, Joslin Diabetes Center, Harvard Medical School One Joslin Place, Boston, Massachusetts, USA

¹Correspondence: Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA. E-mail: george.king{at}joslin.harvard.edu

ABSTRACT

PPAR agonists, thiazolidinediones, cause fluid retention and edema due to unknown mechanisms. We characterized the effect of rosiglitazone (RSG), a thiazolidinedione, to induce vascular permeability, vascular endothelial growth factor (VEGF) expression, and protein kinase C (PKC) activation with edema and wt gain. In lean, fatty and diabetic Zucker rats, and endothelial insulin receptor knockout mice, RSG increased wt and vascular permeability, selectively in fat and retina, but not in heart or skeletal muscle. H₂O content and wt of epididymal fat were increased by RSG and correlated to increases in capillary permeability in fat and body wt. RSG induced VEGF mRNA expression and PKC activation in fat and retina up to 2.5-fold. Ruboxistaurin, a PKCß isoform inhibitor, in the latter 2 wk of a 4-wk study, normalized vascular permeability in fat and decreased total wt gain, H₂O content, and wt of fat vs. RSG alone but did not decrease VEGF expression, basal permeability, or food intake. Finally, RSG did not increase wt or vascular permeability in PKCß knockout vs. control mice. Thus, thiazolidinedione’s effects on edema and wt are partially due to an adipose tissue-selective activation of PKC and vascular permeability that may be prevented by PKCß inhibition.—Sotiropoulos, K. B., Clermont, A., Yasuda, Y., Rask-Madsen, C., Mastumoto, M., Takahashi, J., Della Vecchia, K., Kondo, T., Aiello, L. P., King, G. L. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: Novel mechanism for PPAR agonist’s effects on edema and weight gain.

This article has been cited by other articles:

				V. Vallon, E. Hummler, T. Rieg, O. Pochynyuk, V. Bugaj, J. Schroth, G. Dechenes, B. Rossier, R. Cunard, and J. Stockand Thiazolidinedione-Induced Fluid Retention Is Independent of Collecting Duct {alpha}ENaC Activity J. Am. Soc. Nephrol., April 1, 2009; 20(4): 721 - 729. [Abstract] [Full Text] [PDF]

				M. Pasarica, O. R. Sereda, L. M. Redman, D. C. Albarado, D. T. Hymel, L. E. Roan, J. C. Rood, D. H. Burk, and S. R. Smith Reduced Adipose Tissue Oxygenation in Human Obesity: Evidence for Rarefaction, Macrophage Chemotaxis, and Inflammation Without an Angiogenic Response Diabetes, March 1, 2009; 58(3): 718 - 725. [Abstract] [Full Text] [PDF]

				O. Gealekman, A. Burkart, M. Chouinard, S. M. Nicoloro, J. Straubhaar, and S. Corvera Enhanced angiogenesis in obesity and in response to PPAR{gamma} activators through adipocyte VEGF and ANGPTL4 production Am J Physiol Endocrinol Metab, November 1, 2008; 295(5): E1056 - E1064. [Abstract] [Full Text] [PDF]

				L. Q. Shen, A. Child, G. M. Weber, J. Folkman, and L. P. Aiello Rosiglitazone and Delayed Onset of Proliferative Diabetic Retinopathy Arch Ophthalmol, June 1, 2008; 126(6): 793 - 799. [Abstract] [Full Text] [PDF]